Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 2/20 | 0.54 |
| ▸ | SKP1 | P63208 | 2/20 | 0.54 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | WNT3A | P56704 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486439 | 0.90 | GPR119 (0.65) | MAPTMEN1TSHRKMT2ASMN1; SMN2 | |
| SCHEMBL876797 | 0.87 | CKS1B (0.59) | CKS1BSKP1SKP2MAPTMEN1 | |
| SCHEMBL25312222 | 0.86 | GPR119 (0.51) | CKS1BSKP1SKP2MAPTMEN1 | |
| SCHEMBL4426982 | 0.86 | HRH3 (0.56) | CKS1BSKP1SKP2MAPTMEN1 | |
| Hydrochloric Acid SCHEMBL30385951 | 0.85 | MAPT (0.56) | CKS1BSKP1SKP2MAPTMEN1 | |
| Lithium Ion SCHEMBL29134373 | 0.85 | CKS1B (0.54) | CKS1BSKP1SKP2MAPTMEN1 | |
| SCHEMBL20046124 | 0.85 | GPR119 (0.44) | CKS1BSKP1SKP2MAPTMEN1 | |
| SCHEMBL23120623 | 0.83 | CKS1B (0.50) | CKS1BSKP1SKP2MAPTMEN1 | |
| SCHEMBL14614610 | 0.83 | CKS1B (0.59) | CKS1BSKP1SKP2MAPTMEN1 | |
| SCHEMBL19503439 | 0.82 | HDAC1 (0.54) | GPR119MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053796-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12427144-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| WO-2023141570-A9 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| CN-118059104-A | Compounds and methods for targeted degradation of androgen receptor | 阿尔维纳斯运营股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20240131023-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2024-04-25 | — | — | US | disclosed |
| CN-115175901-B | Compounds and methods for targeted degradation of androgen receptor | 阿尔维纳斯运营股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-11883393-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| WO-2012040137-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012040139-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012024150-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-23 | — | — | WO | disclosed |
| US-7605163-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20080119486-A1 | BENZOYL-PIPERAZINE DERIVATIVES | JOLIDON SYNESE | 2008-05-22 | — | — | US | disclosed |
| US-7319099-B2 | Such as 1-{3-fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl benzoyl)-piperazin-1-yl]-phenyl}-ethanone for treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia, attention deficit disorders, or Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2008-01-15 | — | — | US | disclosed |
| EP-1656361-B1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-01-02 | — | — | EP | disclosed |
| EP-1656361-A1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050209241-A1 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005014563-A1 | PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209241-A1 | Benzoyl-piperazine derivatives | SLC1A2, SLC18A2, SLC6A7 | CKS1B 4628/4885SKP1 1559/4885SKP2 739/4885 |
| US-20260053796-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, NR5A1, KLK3 | CKS1B 154/4885SKP1 1902/4885SKP2 768/4885 |
| US-12427144-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, KLK3, ACP3 | CKS1B 253/4885SKP1 4101/4885SKP2 291/4885 |
| US-11883393-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, KLK3, ACP3 | CKS1B 253/4885SKP1 4101/4885SKP2 291/4885 |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | HTT, HYPK, ATXN2 | CKS1B 3397/4885SKP1 2936/4885SKP2 1584/4885 |
| US-20080119486-A1 | BENZOYL-PIPERAZINE DERIVATIVES | SLC1A2, SLC18A2, SLC6A7 | CKS1B 4628/4885SKP1 1559/4885SKP2 739/4885 |
| US-20240131023-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, KLK3, ACP3 | CKS1B 253/4885SKP1 4101/4885SKP2 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.